



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/789,627-Conf. #7662
				Filing Date	February 26, 2004
				First Named Inventor	Howard KAUFMAN
				Art Unit	1632
				Examiner Name	V. E. Bertoglio
Sheet	1	of	1	Attorney Docket Number	0019240.00461US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/AS/	AA*	US-6,277,599-B1	08-21-2001	Copley et al.	
/AS/	AB*	US-6,190,657-B1	02-20-2001	Pawelek et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
					T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFP. * Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/AS/	CA**	Xiang, R. et al.: "A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 Ligand trimer induces T cell-mediated carcinoembryonic antigen-transgenic mice," 2001, J. Immunol., Vol. 167, 4560-4565.			T ²
/AS/	CB**	Bereta, M.K. et al.: "Construction of a recombinant Salmonella vector displaying anti-CEA antibody: A novel method for targeting colon adenocarcinoma," March 2002. Proc. Am. Assoc. Cancer Res., Vol. 43, page 663.			
/AS/	CC**	International Search Report issued for International Patent Application No. PCT/US2004/005866.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Anoop Singh/	Date Considered	05/03/2007
--------------------	---------------	-----------------	------------

6137761

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

of 1

Complete If Known

Application Number	10/789,627
Filing Date	02/26/04
First Named Inventor	Howard Kaufman
Art Unit	1641 1632
Examiner Name	to be assigned

Attorney Docket Number 5199-49

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Number-Kind Code ² (if known)					
/AS/		US- 6,150,584	11-21-2000	Kucherlapati, et al.	
		US- 6,162,963	12-19-2000	Kucherlapati, et al.	
		US- 6,278,039	08-21-2001	Johnson, et al.	
		US- 6,448,080	09-10-2002	Ward, et al.	
		US- 6,461,864	10-08-2002	Soriano, et al.	
		US- 6,479,284	11-12-2002	Marasco, et al.	
		US- 6,503,712	01-07-2003	Thukral, et al.	
		US- 20020006664	01-17-2002	Sabatini, D.M.	
		US- 20030017549	01-23-2003	Owens, et al.	
/AS/		US- 20030018993	01-23-2003	Guttersen, et al.	
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
Country Code ³ "Number" ⁴ "Kind Code" ⁵ (if known)						
/AS/		WO9932619	12-20-2001	Mushegian, et al.		
		WO0129058	04-26-2001	Mello, et al.		
		WO0168836	09-20-2001	Beach, et al.		
/AS/		WO0196584	12-20-2001	Mushegian, et al.		

Examiner Signature	<i>[Signature]</i>	Date Considered
--------------------	--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Information Disclosure Statement by Applicant <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/789,627
				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1644 1632
				Examiner Name	to be assigned
Sheet	1	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/AS/		Agterberg et al., Outer membrane PhoE protein of Escherichia coli as a carrier for foreign antigenic determinants: immunogenicity of epitopes				
		of foot-and-mouth disease virus.				
		Vaccine, 8: 85-91, 1990 (N/A)				
		Allen et al., The identification, cloning and mutagenesis of a genetic locus required for lipopolysaccharide biosynthesis in Bordetella pertussis.				
		Mol. Microbiol., 19: 37-52, 1996				
		Arakawa et al., Mutant loxP vectors for selectable marker recycle and conditional knock-outs.				
		BMC Biotechnol., 1: 7, 2001				
/AS/		Ashrafi et al., Genome-wide RNAi analysis of <i>Caenorhabditis elegans</i> fat regulatory genes.				
		Nature, 421: 268-272, 2003				

Examiner Signature	<i>an</i>	Date Considered	
--------------------	-----------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/789,627
		Filing Date	02/26/04
		First Named Inventor	Howard Kaufman
		Art Unit	1641
		Examiner Name	to be assigned
Sheet 2	of 38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AS/		Austin et al., A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli	
		cytosine deaminase.	
		Mol. Pharmacol., 43: 380-387, 1993	
		Ausubel et al., eds., Current Protocols in Molecular Biology (New York, NY: John Wiley & Sons, Inc., 2001) <i>(N/A)</i>	
		Bagshawe et al., A cytotoxic agent can be generated selectively at cancer sites.	
		Br. J. Cancer, 58: 700-703, 1988	
		Bang et al., OmpR regulates the stationary-phase acid tolerance response of <i>Salmonella enterica</i> serovar <i>typhimurium</i> .	
		J. Bacteriol., 182: 2245-2252, 2000	
/AS/		Baumler et al., Identification and sequence analysis of <i>lpfABCDE</i> , a putative fimbrial operon of <i>Salmonella typhimurium</i> .	
		J. Bacteriol., 177: 2087-2097, 1995	

Examiner Signature	<i>[Signature]</i>	Date Considered	
--------------------	--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/789,627
<i>(Use as many sheets as necessary)</i>				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	3	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/AS/		Baumler et al., The lpf fimbrial operon mediates adhesion of <i>Salmonella typhimurium</i> to murine Peyer's patches.				
/		Proc. Natl. Acad. Sci. USA, 93: 279-283, 1996				
		Beers and Berkow (eds.), The Merck Manual of Diagnosis and Therapy, 17th ed. (Whitehouse Station, NJ: Merck Research Laboratories, 1999)				
		973-974, 976, 986, 988, 991 — (N/A)				
		Belanger et al., Functional analysis of genes responsible for the synthesis of the B-band O antigen of <i>Pseudomonas aeruginosa</i> serotype				
		O6 lipopolysaccharide.				
		Microbiology, 145: 3505-3521, 1999				
/AS/		Bentala et al., Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide.				
		Shock, 18: 561-566, 2002				

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(Use as many sheets as necessary)					
Sheet	4	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/AS/		Bignami et al., N-(4'-hydroxyphenylacetyl) palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase			
		conjugate.			
		Cancer Res., 52: 5759-5764, 1992			
		Billy et al., Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines.			
		Proc. Natl. Acad. Sci. USA, 98: 14428-14433, 2001			
		Black et al., Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy.			
		Proc. Natl. Acad. Sci. USA, 93: 3525-3529, 1996			
/AS/		Bochner, et al., Positive selection for loss of tetracycline resistance.			
		J. Bacteriol., 143: 926-933, 1980			

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/789,627
				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	5	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/AS/		Boder et al., Yeast surface display for directed evolution of protein expression, affinity, and stability.		
		Methods Enzymol., 328: 430-444, 2000		
		Bone, R. C., Gram-negative sepsis. Background, clinical features, and intervention.		
		Chest, 100: 802-808, 1991		
		Bouterfa et al., Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in established cell lines.		
		Neurosurgery, 46: 419-430, 2000		
		Buchmeier et al., Induction of <i>Salmonella</i> stress proteins upon infection of macrophages.		
		Science, 248: 730-732, 1990		
/AS/		Buttner et al., Functional analysis of HrpF, a putative type III translocon protein from <i>Xanthomonas campestris</i> pv. <i>vesicatoria</i> .		
		J. Bacteriol., 184: 2389-2398, 2002		

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>			Complete if Known		
			Application Number	10/789,627	
			Filing Date	02/26/04	
			First Named Inventor	Howard Kaufman	
			Art Unit	1641	
			Examiner Name	to be assigned	
Sheet	6	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/AS/		Cairns et al., Lymphotactin expression by engineered myeloma cells drives tumor regression: mediation by CD4+ and CD8+ T cells and neutrophils expressing XCR1 receptor.			
		J. Immunol., 167: 57-65, 2001			
		Carneiro et al., p27 deficiency desensitizes Rb-/-cells to signals that trigger apoptosis during pituitary tumor development.			
		Oncogene, 22: 361-369, 2003			
		Cascales et al., Effects of an antitumoural rhodium complex on thioacetamide-induced liver tumor in rats. Changes in the activities of ornithine decarboxylase, tyrosine aminotransferase and of enzymes involved in fatty acid and glycerolipid synthesis.			
		Biochem. Pharmacol., 35: 2655-2661, 1986			
/AS/		Charbit et al., Presentation of two epitopes of the preS2 region of hepatitis B virus on live recombinant bacteria.			
		J. Immunol., 139: 1658-1664, 1987			

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
<i>(Use as many sheets as necessary)</i>			
Sheet	7	of	38
		Attorney Docket Number	
		5199-49	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AS/		Cheng et al., Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective.	
		Nat. Med., 9(3): 338-342, 2003	
		Christmann et al., Epitope mapping and affinity purification of monospecific antibodies by Escherichia coli cell surface display of gene-derived random peptide libraries.	
		J. Immunol. Methods, 257: 163-173, 2001	
		Chu et al., Toward highly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies.	
		J. Virol., 71: 720-725, 1997	
/AS/		Clairmont et al., Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of <i>Salmonella typhimurium</i> .	
		J. Infect. Dis., 181: 1996-2002, 2000	

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/789,627
				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	8	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/AS/		Clodi et al., Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance.				
		Cancer, 94: 1-5, 2002				
		Cottrell et al., Silence of the strands: RNA interference in eukaryotic pathogens.				
		Trends Microbiol., 11: 37-43, 2003 (N/A)				
		Daugherty et al., Development of an optimized expression system for the screening of antibody libraries displayed on the Escherichia coli surface.				
		Protein Eng., 12: 613-621, 1999				
/AS/		DeFilippis et al., Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in				
		HeLa cervical carcinoma cells.				
		J. Virol., 77: 1551-1563, 2003				

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/789,627
				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	9	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/AS/		Earhart, C.F., Use of an Lpp-OmpA fusion vehicle for bacterial surface display.			
		Methods Enzymol., 326: 506-516, 2000			
		Escobar et al., RNAi-mediated oncogene silencing confers resistance to crown gall tumorigenesis.			
		Proc. Natl. Acad. Sci. USA, 98: 13437-13442, 2001			
		Fefer, "Special delivery" to cancer cells.			
		Blood, 99: 1503-1504, 2002			
		Feldhaus et al., Flow-cytometric isolation of human antibodies from a nonimmune <i>Sacharomyces cerevisiae</i> surface display library.			
		Nat. Biotechnol., 21(2): 163-170, 2003			
/AS/		Fields et al., Mutants of <i>Salmonella typhimurium</i> that cannot survive within the macrophage are avirulent.			
		Proc. Natl. Acad. Sci. USA, 83: 5189-5193, 1986			

Examiner Signature		Date Considered
--------------------	---	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/789,627
				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	10	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/AS/		Fire et al., Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> .			
		Nature, 391: 806-811, 1998			
		Folders et al., Characterization of <i>Pseudomonas aeruginosa</i> chitinase, a gradually secreted protein.			
		J. Bacteriol., 183: 7044-7052, 2001			
		Folster et al., The extracellular transport signal of the <i>Vibrio cholerae</i> endochitinase (ChiA) is a structural motif located between amino			
		acids 75 and 555.			
		J. Bacteriol., 184: 2225-2234, 2002			
/AS/		Francisco et al., Production and fluorescence-activated cell sorting of <i>Escherichia coli</i> expressing a functional antibody fragment on the			
		external surface.			
		Proc. Natl. Acad. Sci. USA, 90: 10444-10448, 1993			

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/789,627
(Use as many sheets as necessary)				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	11	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AS/		Francisco et al., Transport and anchoring of beta-lactamase to the external surface of Escherichia coli.	
		Proc. Natl. Acad. Sci. USA, 89: 2713-2717, 1992	
		Frengen et al., Modular bacterial artificial chromosome vectors for transfer of large inserts into mammalian cells.	
		Genomics, 68: 118-126, 2000	
		Friedman et al., Has the mortality of septic shock changed with time.	
		Crit. Care Med., 26: 2078-2086, 1998	
/AS/		Galan et al., Cloning and characterization of the asd gene of <i>Salmonella</i> typhimurium: use in stable maintenance of recombinant plasmids in	
		Salmonella vaccine strains.	
		Gene, 94: 29-35, 1990	

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(Use as many sheets as necessary)					
Sheet	12	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AS/		Georgiou et al., Display of beta-lactamase on the Escherichia coli surface: outer membrane phenotypes conferred by Lpp'-OmpA'-beta-lactamase	
		fusions.	
		Protein Eng., 9: 239-247, 1996	
		Ghosh et al., Chitinase secretion by encysting Entamoeba invadens and transfected Entamoeba histolytica trophozoites: localization of secretory	
		vesicles, endoplasmic reticulum, and Golgi apparatus.	
		Infect. immune., 67: 3073-3081, 1999	
/AS/		Ghosh et al., Role of superoxide dismutase in survival of Leishmania within the macrophage.	
		Biochem. J., 369: 447-452, 2003	

Examiner Signature		Date Considered
--------------------	---	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/789,627
				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	13	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/AS/		Guo et al., Par-1, A gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed.				
		Cell, 81: 611-620, 1995				
		Haenseler et al., Activation of methotrexate-alpha-alanine by carboxypeptidase A-monoclonal antibody conjugate.				
		Biochemistry, 31: 891-897, 1992				
/AS/		Haisma et al., Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate.				
		Cancer Immunol. Immunother., 34: 343-348, 1992				

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/789,627
				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	14	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/AS/		Haisma et al., A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific			
		treatment of cancer.			
		Br. J. Cancer, 66: 474-478, 1992			
		Harrison et al., Presentation of foreign antigenic determinants at the bacterial cell surface using the TraT lipoprotein.			
		Res. Microbiol., 141: 1009-1012, 1990			
		Hatse et al., Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation.			
		Biochem. Pharmacol., 58: 539-555, 1999			
/AS/		Hedegaard et al., Type 1 fimbriae of Escherichia coli as carriers of heterologous antigenic sequences.			
		Gene, 85: 115-124, 1989			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/789,627
(Use as many sheets as necessary)				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	15	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/AS/		Heinrichs et al., Apoptosis or growth arrest: modulation of the cellular response to p53 by proliferative signals.				
		Oncogene, 22:555-571, 2003				
		Hirvas et al., Mutants carrying conditionally lethal mutations in outer membrane genes omsA and firA (ssc) are phenotypically similar, and				
		omsA is allelic to firA.				
		EMBO J., 10: 1017-1023, 1991				
		Hofnung, Expression of foreign polypeptides at the Escherichia coli cell surface.				
		Methods Cell Biol., 34: 77-105, 1991				
/AS/		Hsu et al., Induction of p21 (CIP1/Waf1) and activation of p34 (cdc2) involved in retinoic acid-induced apoptosis in human hepatoma				
		Hep3B cells.				
		Exp. Cell Res., 248: 87-96, 1999				

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(Use as many sheets as necessary)					
Sheet	16	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AS/		Hui et al., A combinatorial approach toward analyzing functional elements of the Escherichia coli hemolysin signal sequence.	
		Biochemistry, 41: 5333-5339, 2002	
		Huser et al., Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors.	
		Nat. Biotechnol., 19: 451-455, 2001	
		Hymowitz et al., Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.	
		Mol. Cell, 4: 563-571, 1999	
		Isticato et al., Surface display of recombinant proteins on Bacillus subtilis spores.	
		J. Bacteriol., 183: 6294-6301, 2001	
/AS/		Johnson et al., Structural characterization of monophosphoryl lipid A homologs obtained from Salmonella Minnesota Re595 lipopolysaccharide.	
		J. Biol. Chem., 265: 8108-8116, 1990	

Examiner Signature		Date Considered
--------------------	---	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(Use as many sheets as necessary)					
Sheet	17	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AS/		Johnstone et al., A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1.	
		Mol. cell Biol., 16: 6945-6956, 1996	
		Kanegasaki et al., Structure-activity relationship of lipid A : comparison of biological activities of natural and synthetic lipid A's with different fatty	
		acid compositions.	
		J. Biochem. (Tokyo), 99: 1203-1210, 1986	
/AS/		Kelly et al., The firA gene of Escherichia coli encodes UDP-3-O-(R-3-hydroxymyristoyl)-glucosamine N-acyltransferase.	
		The third step of endotoxin biosynthesis.	
		J. Biol. Chem., 268: 19866-19874, 1993	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/789,627
Sheet	18	of	38	Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
				Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/AS/		Kerr et al., Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide.			
		Cancer Immunol. Immunother., 31: 202-206, 1990			
		Khan et al., A lethal role for lipid A in <i>Salmonella</i> infections.			
		Mol. Microbiol., 29: 571-579, 1998			
		Khayyamian et al., ICOS-ligand, expressed on human endothelial cells, constitutively stimulates Th1 and Th2 cytokine secretion by memory CD4+ T cells.			
		Proc. Natl. Acad. Sci. USA, 99: 6198-6203, 2002			
/AS/		Kjaergaard et al., Antigen 43-mediated autotransporter display, a versatile bacterial cell surface presentation system.			
		J. Bacteriol., 184: 4197-4204, 2002			

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>		Complete if Known	
		Application Number	10/789,627
		Filing Date	02/26/04
		First Named Inventor	Howard Kaufman
		Art Unit	1641
		Examiner Name	to be assigned
Sheet	19	of	38
		Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AS/		Klena et al., Cloning, sequencing, and characterization of the lipopolysaccharide biosynthetic enzyme heptosyltransferase I gene	
		(waaC) from <i>Campylobacter jejuni</i> and <i>Campylobacter coli</i> .	
		Gene, 222: 177-185, 1998	
		Knox et al., A new cytotoxic, DNA interstrand crosslinking agents, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from	
		5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.	
		Biochem. Pharmacol., 37: 4661-4669, 1988	
/AS/		Kokoris et al., Characterization of Herpes Simplex Virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity.	
		Protein Sci., 11: 2267-2272, 2002	

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/789,627
				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	20	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/AS/		Kononova et al., The primary structure of the N-terminal region of mature alkaline phosphatase is critical for secretion and function of the enzyme.				
		Biochemistry (Mosc.), 65: 1075-1081, 2000 (N/A)				
		Kornacker et al., Molecular characterization of pula and its product, pullulanase, a secreted enzyme of Klebsiella pneumoniae UNF 5023.				
		Mol. Microbiol., 4: 73-85, 1990				
		Koronakis et al., Isolation and analysis of the C-terminal signal directing export of Escherichia coli hemolysin protein across both bacterial				
		membranes.				
		EMBO J., 8: 595-605, 1989				
/AS/		Kwong et al., The suppression of colon cancer cell growth in nude mice by targeting beta-catenin/TCF pathway.				
		Oncogene, 21: 8340-8346, 2002				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(Use as many sheets as necessary)			
Sheet	21	of	38
		Attorney Docket Number	
		5199-49	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AS/		Lamping et al., LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria.	
		Clin. Invest., 101: 2065-71268, 1998	
		Laochumroonvorapong et al., Perforin, a cytotoxic molecule which mediates cell necrosis, is not required for the early control of focal adhesion kinase	
		by caspases during apoptosis.	
		J. Biol. Chem., 272: 26056-26061, 1997	
		Lee et al., The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis.	
		Genes Dev., 15: 455-466, 2001	
/AS/		Liu et al., Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c.	
		Cell, 86: 147-157, 1996	

Examiner Signature		Date Considered
--------------------	---	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for, form 1449/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(Use as many sheets as necessary)					
Sheet	22	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AS/		Lloyd et al., Molecular characterization of type III secretion signals via analysis of synthetic N-terminal amino acid sequences.	
		Mol. Microbiol., 43: 51-59, 2002	
		Low et al., Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo.	
		Nat. Biotechnol., 17: 37-41, 1999	
		Lu et al., Polymerizable Fab' antibody fragments for targeting of anticancer drugs.	
		Nat. Biotechnol., 17: 1101-1104, 1999	
		Lu et al., Activation of multiple caspases and modification of cell surface fas (CD95) in proteasome inhibitor-induced apoptosis of rat natural killer cells.	
		J. Cell Biochem., 88: 482-492, 2003	
/AS/		Mackman et al., Release of a chimeric protein into the medium from <i>Escherichia coli</i> using the C-terminal secretion signal of haemolysin.	
		EMBO J., 6: 2835-2841, 1987	

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/789,627	
			Filing Date	02/26/04	
			First Named Inventor	Howard Kaufman	
			Art Unit	1641	
			Examiner Name	to be assigned	
Sheet	23	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/AS/		Maniatis et al., Molecular Cloning: A Laboratory Manual, 2nd ed. (Cold Spring Harbor: Cold Spring Harbor Laboratory, 1989) (N/A)			
		Marolda et al., Identification, expression, and DNA sequence of the GDP-mannose biosynthesis genes encoded by the O7 rfb gene cluster			
		of strain			
		VW187 (Escherichia coli O7: K1).			
		J. Bacteriol., 175: 148-158, 1993			
		Martinez-Canamero et al., mlpB, a gene encoding a new lipoprotein in Myxococcus xanthus.			
		J. Appl. Microbiol., 92: 134-139, 2002 (N/A)			
/AS/		Mastrobattista et al., Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-			
		entrapped proteins.			
		J. Biol. Chem., 277: 27135-27143, 2002			

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known
Sheet	24	of	38	Attorney Docket Number
				5199-49

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/AS/		Maxwell and Rivera, Proline oxidase induces apoptosis in tumor cells and its expression is absent or reduced in renal carcinoma.		
		J. Biol. Chem., e-publication ahead of print, 2003		
		Mei et al., Optimization of tumor-targeted gene delivery by engineered attenuated <i>Salmonella typhimurium</i> .		
		Anticancer Res., 22: 3261-3266, 2002		
		Meyer et al., Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models.		
		Cancer Res., 53: 3956-3963, 1993		
/AS/		Mills et al., Trafficking of porin-deficient <i>Salmonella typhimurium</i> mutants inside HeLa cells: ompr and envZ mutants are defective for the formation of <i>Salmonella</i> -induced filaments.		
		Infect. Immun., 66: 1806-1811, 1998		

Examiner Signature		Date Considered
--------------------	---	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/789,627
(Use as many sheets as necessary)				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	25	of	38	Attorney Docket Number	
5199-49					

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/AS/		Moolten et al., Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors.			
		J. Natl. Cancer Inst., 82(4): 297-300, 1990			
		Morishima et al., An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9			
		by caspase-12.			
		J. Biol. Chem., 277: 34287-34294, 2002			
/AS/		Mullen et al., Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system.			
		Proc. Natl. Acad. Sci. USA, 89: 33-37, 1992			

Examiner Signature		Date Considered
--------------------	---	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
<i>(Use as many sheets as necessary)</i>			
Sheet	26	of	38
		Attorney Docket Number	
		5199-49	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AS/		Mullen et al., Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor.	
		Cancer Res., 54: 1503-1506, 1994	
		Nakamoto et al., Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy.	
		J. Exp. Med., 196: 1105-1111, 2002	
		Nauts et al., A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man.	
		Acta Medica. Scandinavica, 145(Suppl. 276): 1-102, 1953	
/AS/		Newton et al., Immune response to cholera toxin epitope inserted in <i>Salmonella</i> flagellin.	
		Science, 244: 70-72, 1989	

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/789,627
(Use as many sheets as necessary)				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	27	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/AS/		Ng et al., An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells.				
		Proc. Natl. Acad. Sci. USA, 99: 10706-10711, 2002				
		Nikolaev et al., Parc. A cytoplasmic anchor for p53.				
		Cell, 112, 29-40, 2003				
		Nishiyama et al., Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules.				
		Cancer Res., 45: 1753-1761, 1985				
/AS/		Norris et al., Phase variation of the lpf operon is a mechanism to evade cross-immunity between Salmonella serotypes.				
		Proc. Natl. Acad. sci. USA, 96: 13393-13398, 1999				

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/789,627
<i>(Use as many sheets as necessary)</i>				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	28	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/AS/		Numasaki et al., Interleukin-17 promotes angiogenesis and tumor growth.				
		Blood, 101(7): 2620-2627, 2003				
		Oltvai et al., Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.				
		Cell, 74: 609-619, 1993				
		Opal et al., Endotoxin as a drug target.				
		Crit. Care Med., 31: S57-64, 2003				
/AS/		Oscarsson et al., Characterization of a pore-forming cytotoxin expressed by Salmonella enterica serovars typhi and paratyphi A.				
		Infect. Immun., 70: 5759-5769, 2002				

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/789,627
				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	29	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AS/		Pedersen et al., Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention.	
		Biochim. Biophys. Acta, 1555: 14-20, 2002	
		Potter et al., Cloning and characterization of the galE locus of Pasteurella haemolytica A1.	
		Infect. Immun., 64: 855-860, 1996	
		Pugsley et al., Two distinct steps in pullulanase secretion by Escherichia coli K12.	
		Mol. Microbiol., 5: 865-873, 1991	
/AS/		Puricelli et al., Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells.	
		Int. J. Cancer, 100: 642-653, 2002	

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/789,627
				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	30	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AS/		Quaife et al., Ectopic expression of metallothionein-III causes pancreatic acinar cell necrosis in transgenic mice.	
		Toxicol. Appl. Pharmacol., 148: 148-157, 1998	
		Raetz, Bacterial endotoxins: extraordinary lipids that activate eukaryotic signal transduction.	
		J. Bacteriol., 175: 5745-5753, 1993	
		Ramachandra et al., Inhibition of lipid A- and lipopolysaccharide-induced cytokine secretion, B cell mitogenesis, and lethal shock by lipid A-specific murine monoclonal antibodies.	
		J. Infect. Dis., 167: 1151-1159, 1993	
/AS/		Roffler et al., Anti-neoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate.	
		Biochem. Pharmacol., 42: 2062-2065, 1991	

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/789,627	
			Filing Date	02/26/04	
			First Named Inventor	Howard Kaufman	
			Art Unit	1641	
			Examiner Name	to be assigned	
Sheet	31	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/AS/		Rothenberg et al., Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression.		
		Proc. Natl. Acad. Sci. USA, 92: 8960-8964, 1995		
		Roy et al., Mutations in firA, encoding the second acyltransferase in lipopolysaccharide biosynthesis, affect multiple steps in lipopolysaccharide biosynthesis.		
		J. Bacteriol., 176: 1639-1646, 1994		
		Rundle et al., Association between the ras p21 oncoprotein in blood samples and breast cancer.		
		Cancer Lett., 185: 71-78, 2002		
		Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed. (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989) (N/A)		
/AS/		Samuelson et al., Cell surface display of recombinant proteins on Staphylococcus carnosus.		
		J. Bacteriol., 177: 1470-1476, 1995		

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/789,627
(Use as many sheets as necessary)				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	32	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
/AS/		Sebastiani et al., Host immune response to <i>Salmonella enterica</i> serovar <i>Typhimurium</i> infection in mice derived from wild strains.				
		Infect. Immun., 70: 1997-2009, 2002				
		Shah et al., The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation.				
		J. Biol. Chem., 277: 25313-25322, 2002				
		Shi, Y., Mechanisms of caspase activation and inhibition during apoptosis.				
		Mol. Cell, 9: 459-470, 2002				
/AS/		Simula et al., Heterologous expression of drug-metabolizing enzymes in cellular and whole animal models.				
		Toxicology, 82: 3-20, 1993				

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/789,627
				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	33	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/AS/		Singer et al., The tumor growth-inhibiting cell adhesion molecule CEACAM1 (C-CAM) is differently expressed in proliferating and quiescent epithelial cells and regulates cell proliferation.			
		Cancer Res., 60: 1236-1244, 2000			
		Springer et al., Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2.			
		J. Med. Chem., 33: 677-681, 1990			
		Stahl et al., Bacterial surface display: trends and progress.			
		Trends Biotechnol., 15: 185-192, 1997 (N/A)			
/AS/		Stein et al., Oligodeoxynucleotides as inhibitors of gene expression: a review.			
		Cancer Res., 48: 2659-2668, 1998			

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/789,627
				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	34	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AS/		Steinbrecher et al., Targeted inactivation of the mouse guanylin gene results in altered dynamics of colonic epithelial proliferation.	
		Am. J. Pathol., 161: 2169-2178, 2002	
		Sutterlin et al., The correlation of c-erbB-2 oncoprotein and established prognostic factors in human breast cancer.	
		Anticancer Res., 20: 5083-5088, 2000	
		Tan et al., Engineering a novel secretion signal for cross-host recombinant protein expression.	
		Protein Eng., 15: 337-345, 2002	
		Tang et al., Induction and characterization of heat shock proteins of <i>Salmonella typhi</i> and their reactivity with sera from patients with typhoid fever.	
		Infect. Immun., 65: 2983-2986, 1997	
/AS/		Tannenbaum et al., The CXC chemokines IP-10 and Mig are necessary for IL-12 mediated regression of the mouse RENCA tumor.	
		J. Immunol., 161: 927-932, 1998	

Examiner Signature		Date Considered
--------------------	---	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(Use as many sheets as necessary)					
Sheet	35	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AS/		Tavian et al., Stable expression of antisense urokinase mRNA inhibits the proliferation and invasion of human hepatocellular carcinoma cells.	
		Cancer Gene Ther., 10: 112-120, 2003	
		van den Berg et al., High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma.	
		Am. J. Pathol., 154: 1685-1691, 1999	
/AS/		van Deventer et al., Transfection of macrophage inflammatory protein 1 alpha into B16F10 melanoma cells inhibits growth of pulmonary metastases but not subcutaneous tumors.	
		J. Immunol., 169: 1634-1639, 2002	

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known

Substitute for form 1449/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(Use as many sheets as necessary)					
Sheet	36	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AS/		Venters et al., Tumor necrosis factor-alpha induces neuronal death by silencing survival signals generated by the type I insulin-like growth	
		factor receptor.	
		Ann. N. Y. Acad. Sci., 917: 210-220, 2000	
		Vile et al., Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas	
		following direct intratumoral injection of DNA.	
		Cancer Res., 53: 3860-3864, 1993	
		Vrudhula et al., Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate.	
		J. Med. Chem., 36: 919-923, 1993	
/AS/		Wagner et al., Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1.	
		Proc. Natl. Acad. Sci. USA, 78: 1441-1445, 1981	

Examiner Signature		Date Considered	
--------------------	---	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(Use as many sheets as necessary)					
Sheet	37	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AS/		Westphal et al., Transposon-generated 'knock-out' and 'knock-in' gene-targeting constructs for use in mice.	
		Curr. Biol., 7: 530-533, 1997	
		Wilda et al., Killing of leukemic cells with a BCR/ABL fusion gene RNA interferences (RNAi).	
		Oncogene, 21: 5716-5724, 2002	
		Woodward et al., Stimulation and inhibition of uveal melanoma invasion by HGF, GRO, IL-1alpha and TGF-beta.	
		Invest Ophthalmol. Vis. Sci., 43: 3144-3152, 2002	
		Wu et al., Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers.	
		Immunotechnology, 2: 21-36, 1996 (N/A)	
/AS/		Yu et al., Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor.	
		Science, 297: 259-263, 2002	

Examiner Signature		Date Considered
--------------------	---	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/789,627
				Filing Date	02/26/04
				First Named Inventor	Howard Kaufman
				Art Unit	1641
				Examiner Name	to be assigned
Sheet	38	of	38	Attorney Docket Number	5199-49

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/AS/		Zhang et al., An anti-sense construct of full-length ATM cDNA imposes a radiosensitive phenotype on normal cells.			
		Oncogene, 17: 811-888, 1998			
		Zhou et al., Radiation and the Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells			
		overexpressing cyclin D1.			
		Cancer Res., 60(10): 2611-2615, 2000			
		Zou et al., Systemic tumor suppression by the proapoptotic gene bik.			
		Cancer Res., 62: 8-12, 2002			
/AS/		Zou et al., Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3.			
		Cell, 90: 405-413, 1997			

Examiner Signature	/Anoop Singh/	Date Considered	05/03/2007
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.